Chronic allograft injury (CAI) results from a humoral response to mismatches in immunogenic epitopes between the donor and recipient. Although alloantibodies against HLA antigens contribute to the pathogenesis of CAI, alloantibodies against non-HLA antigens likely contribute as well. Here, we used highdensity protein arrays to identify non-HLA antibodies in CAI and subsequently validated a subset in a cohort of 172 serum samples collected serially post-transplantation. There were 38 de novo non-HLA antibodies that significantly associated with the development of CAI (P,0.01) on protocol post-transplant biopsies, with enrichment of their corresponding antigens in the renal cortex. Baseline levels of preformed antibodies to MIG (also called CXCL9), ITAC (also called CXCL11), IFN-g, and glial-derived neurotrophic factor positively correlated with histologic injury at 24 months. Measuring levels of these four antibodies could help clinicians predict the development of CAI with .80% sensitivity and 100% specificity. In conclusion, pretransplant serum levels of a defined panel of alloantibodies targeting non-HLA immunogenic antigens associate with histologic CAI in the post-transplant period. Validation in a larger, prospective transplant cohort may lead to a noninvasive method to predict and monitor for CAI.
Despite improvements in short-term graft survival over the past decades, 1 chronic allograft injury (CAI) remains a major challenge in renal and other solid organ transplants. In addition, the rate of progression of CAI remained relatively unabated over the last decade, with limited improvements in extending graft survival. 2, 3 CAI in the graft is the primary reason for accelerated graft loss, 4 categorized by progressive interstitial fibrosis (IF) and tubular atrophy (TA) of the parenchyma, 5 that is also associated with glomerulopathy, fibrointimal hyperplasia of arteries, and arteriolar hyalinosis. 6 This injury is believed to be mostly a humoral injury response to mismatched immunogenic epitopes between the donor and recipient, 7 with current understanding mostly focused on HLA antigens. 8 Despite improved understanding of the assessment and monitoring for HLA mismatched epitopes, 8 the pathogenicity of donor-specific anti-HLA antibodies on CAI remains elusive. 9 This is shown with complete HLA matched transplants exhibiting finite survival due to progressive CAI, 10 and not infrequently, CAI observed in HLA mismatched grafts without demonstrable antibodies to donor-specific HLA antigens. 7 These findings strongly suggest that additional pathogenic antibodies drive the humoral axis of injury in CAI, 9, 11 and may be the final common outcome. The activation or transition of these non-HLA antibodies toward pathogenicity is likely through the underlying triggers of acute rejection, hypoperfusion, ischemia reperfusion, calcineurin toxicity, infection, and recurrent diseases. 12 Currently, there is no means to predict which transplant patients will develop accelerated CAI in the allograft. Histologic diagnosis of CAI is the current gold standard for diagnosing CAI; however, this only detects advanced, established, and often irreversible injury. The renal biopsy is also an invasive procedure that suffers from sampling heterogeneity, is associated with various complications, 13 and provides a limited prognostic value. Identification of informative, minimally invasive biomarkers is critically needed to monitor and predict CAI, and remains a critically important unmet need in solid organ transplantation.
The antibody axis has been implicated in different disease conditions, and profiling and measuring the level of IgG antibodies against thousands of defined human proteins to identify antibodies against non-HLA antigens have been previously attempted in autoimmune diseases 14 and CKD. 15 In an attempt to evaluate clinically relevant de novo, renal-specific, non-HLA antibody responses, we utilized protein arrays and customized informatics for studying non-HLA antibody responses in stable grafts 16, 17 and acute rejection 11, 18 to interrogate previously unidentified non-HLA antibody CAI. To investigate the non-HLA pathogenicity in CAI, we excluded patients with signs of acute rejection, purely focusing on non-HLA antibody responses in the absence of any interval acute rejection episodes. From this cohort, we then excluded pediatric patients with interval episodes of infection, delayed graft function, or body surface area ,0.75 m 2 , 19 thus creating a homogenous set of patients without any major confounders to CAI. This resulted in the removal of 47 patients with interval acute rejection episodes, 3 patients in interval infectious episodes, 3 patients with delayed graft function, as well as 4 recipients with body surface area ,0.75 m 2 . From these remaining patients, we carefully selected a subset of 20 patients (n=10 CAI versus n=10 without CAI) as the learning set and collected surveillance samples of sera matched to diagnostic biopsy at 0, 6, and 24 months post-transplantation from each patient, thus analyzing 60 serum samples for diagnosis and prediction of CAI. The increased presence of significant non-HLA antibodies was analyzed for their correlation with injury progression post-transplant. Finally, from the larger confounder-controlled cohort, we validated the most significant and relevant antibodies (from discovery) by using ELISAs on 112 unique and independent sera samples from 68 patients (Figure 1 ).
RESULTS

Identification of CAI-Specific Novel Non-HLA Antibodies
Compared with the non-HLA antibody levels before transplantation, there was a significant immune responseposttransplant with the development of CAI. By using M-statistics of the Prospector Analyzer with the robust linear normalization method published elsewhere, 20 we identified a total of 231 non-HLA antibodies with statistically significant P values #0.05. Among the 231 changed antibodies, 111 non-HLA antibodies increased significantly in the CAI group (P#0.05) (Figure 2A and Supplemental Table 1 ). On the basis of a time course analysis of the most statistically significant (P#0.05) non-HLA antibodies, the CAI-specific non-HLA antibody could be categorically divided into an non-HLA showing significant detection either early (,6 months) or late (.6 months) post-transplantation. The early response was observed to be against non-HLA proteins involved in pathways such as cell-mediated immune response, connective tissue development and function, and EGF signaling. Some of these selected antigens are shown in Table 1 . The late responding non-HLA proteins were noted to immunologically reactive proteins involved in pathways such as cell death, cell-tocell signaling and interaction, and cellular movement ( Figure 2B and Supplemental Figure 1) .
We analyzed the antibody response for 12 HLA antigens, including 2 HLA class I molecules (HLA-B and HLA-C) and 10 HLA class II molecules (HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, and HLA-DRB5) in the CAI and non-CAI groups. The signal intensity of antibody detection to these targets is very low (average ,500 RFU signal intensity). Thus, it seems that HLA antibody levels may be less influenced in the course of CAI, in the absence of interval acute rejection.
Cross-Mapping CAI-Specific Non-HLA Antibodies to Expression of the Target Proteins in Subcellular Compartments of the Kidney
To triage the selection of non-HLA antibodies to further pursue, we chose to assign physiologic and potentially pathologic relevance to the significant CAI-specific antibodies, by selecting antibodies with reactivities to kidney-specific antigens. The assumption is that these de novo antibody responses after kidney transplantation are more likely against the antigens in the newly transplanted kidney. To enable this analysis, we performed crossmapping of kidney and kidney-compartment-specific genes obtained from microdissected compartments of normal kidney by profiling these tissues on cDNA microarrays with protoarray protein targets, using our published approach of integrated antibiomics. 18, 21, 22 This analysis revealed that there was an enrichment for antigens expressed in the renal cortex (P=0.029). As previously shown, the renal pelvis antigens are highly immunogenic, and enrichment for pelvis-specific antigens was also noted. These antigen lists are shown in Table 2 .
CAI-Specific Antibodies Track Injury Progression
We took the antibodies that were increased with CAI and performed Spearman correlation analyses with the Chronic Allograft Damage Index (CADI) and IF/TA scores of each corresponding renal biopsy. A total of 34 antibodies and 41 antibodies demonstrated a positive correlation with CADI score (overall P,0.04) and IF/TA (overall P,0.04), respectively. The top 20 antibodies are listed in Table 3 . Pathway analysis suggested that these antigens are involved in cellular movement, antigen presentation, cell-to-cell signaling and interaction, and cell death (P,0.002). Scatter plots for the six most significant antibodies (IFNG [IFN-g], MIG, CSNK2A2, CCL21, glial cell-derived neurotrophic factor [GDNF] , and ITAC) and their correlation with the CADI score are presented in Figure 3 .
Predicting Injury Progression after Transplantation
As shown by our group in a previous publication, 15 chronic renal injury and end stage renal failure result in uncovering of kidney-specific epitopes, mostly in the renal cortex and the renal pelvis, and the immunologic recognition of these newly discovered non-HLA antigens with humoral responses in the form of non-HLA antibodies, specific to chronic renal injury. To evaluate if this repertoire of preformed non-HLA antibodies specific to chronic renal failure could predict the subsequent development of CAI after kidney transplantation, the level of these non-HLA antibodies was evaluated at the baseline (day 0 sera) of each patient. Spearman correlation analysis was performed to identify the specificities or levels with the progression of CAI on the biopsy performed at 6 months and 24 months after transplantation. Interestingly, baseline levels of these preformed antibodies to MIG, ITAC, IFNG, GABPA, and GDNF positively correlated (P,0.05) with CADI score at 6 months, and baseline levels of four of these five antibodies (MIG, ITAC, IFNG, GDNF), as well as two additional antibodies to IL-8 and CCL21, all positively correlated (P=0.04) with CADI score at 24 months ( Table 4) . As expected for this selection of antibodies, antibody levels at 6 months post-transplant for IL-8, MIG, IL21, CCL19, LRRK2, CCL21, GDNF, and IFNG also correlated with CAI at 24 months post-transplantation, suggesting that these antibody levels could also be tracked for progression of CAI in both the pretransplant period (preformed) and the post-transplant period (de novo) (Figure 4 , A-D) ( Table 4) .
Univariate and multivariate logistic regressions were performed to examine the relationship between the baseline signal intensities of each of the preformed four antibodies (MIG, ITAC, GDNF, and IFNG) and CADI scores from the protocol biopsies performed in these same patients at 6 and 24 months post-transplantation. A CADI score of $3 was used as a cutoff to define either severe ($3 CADI score) or mild (,3 CADI score) histologic CAI. The receiver operating characteristic (ROC) curves for each of these antibodies to predict the development of CAI are shown for the 6-month protocol biopsy ( Figure 4E ) and the 24-month protocol biopsy ( Figure 4F ). When a regression model was built by univariate analysis, detection of baseline levels of preformed antibody to MIG at levels .200 RFU had a significant association with the patient developing CAI on the protocol biopsy at both 6 months (odds ratio, 1.04; 95% confidence limit, 1.003-1.078; P=0.034), and at 24 months posttransplantation (odds ratio, 1.023; 95% confidence limit, 1.001-1.045; P=0.0375). Patients who never developed CAI had baseline antibody levels to MIG of ,50 RFU.
Validation of Selected Potential Antibody Biomarkers
ELISAs were developed and optimized to demonstrate that discovery of target non-HLA antibodies by protoarray could be validated by ELISA. ELISAs were set up, customized, and performed for some selected (and significant) targets in which the full-length proteins could be commercially obtained from stock supplies for setting up the reverse ELISAs for antibody measurements. These assays were done for MIG, ITAC, CSNK2A2, and PDGFRA. A significant increase in the antibody levels were confirmed in CAI by reverse ELISA for all four targets: MIG (P,0.02), ITAC (P,0.014), CSNK2A2 (P,0.0002), and PDGFRA (P,0.0001) ( Figure 5 , A-D). For further validation, seven independent patients were selected, who were not used for discovery by protoarrays, in whom serial sera and matched protocol biopsies were available and who had a CAI grade of at least .3 on both the 6-month and the 24-month protocol biopsies. Three of these targets were confirmed by our customized reverse ELISA to also show significant increases in this longitudinal analysis. Antibody levels for patients with CAI at 24 months were significantly higher in 24-month sera versus 6-month sera for CSNK2A2 (P=0.05), ITAC (P=0.05), and MIG (P=0.005) ( Figure 5 , E and F). In addition, there was a strong correlation of two of these antibody levels with CADI scores on the 24-month protocol biopsies (MIG: r=0.62, P=0.05; ITAC: r=0.62, P=0.05). A novel approach is used to identify novel non-HLA antibodies through an integrative approach of analyzing sera samples with matched biopsies on protein microarray for the discovery step. The validation step is performed after filtering the data for highly correlated antibodies for renal graft injury. The highly correlated antibodies are then validated by indirect ELISAs on an independent set of patients for cross-sectional and longitudinal analyses. nCAI, non-CAI; STA, stable.
DISCUSSION
CAI is related to a humoral response driven by alloantibodies against HLA antigens, with recent data also supporting a role for immunogenic non-HLA renal antigens. An understanding of the specificities and correlative levels of these antibodies can provide an understanding of molecular injury triggers in CAI and a means to noninvasively monitor the development of this injury. Despite the contribution of newly available immunosuppressive drugs in the short-term survival of the transplanted kidney, 3 CAI progresses relentlessly post-transplant, accelerating the risk for graft loss. There is a lack of reliable and robust noninvasive biomarkers to track the health status of the transplanted organ, without the requirement of serial protocol biopsies. Elaborating injury mechanisms and developing predictive, noninvasive monitoring methods for CAI is an important unmet clinical need. 2, 23 The process of biologic tissue injury from events such as exposure to calcineurin inhibitor agents, from graft ischemia, or from recipient hypertension, likely results in the alteration of the levels, exposure, or targeting for various proteins/antigens in the renal allograft. These altered antigens mount specific antibody responses. The ability to recognize these relevant antigens, to measure these specific antibody levels in the circulation, and to correlate these levels with histologic CAI in the allograft itself is a powerful approach to identify noninvasive, clinically relevant serological biomarkers for detecting and predicting CAI. Our initial studies strongly suggested a pathogenic role for non-HLA antibodies after transplantation. 11, 16, 18 From gene expression analyses, we reported an increased level of Ig gene transcripts as a function graft injury. 24 We thus hypothesized that accumulated organ injury in the form of CAI could be associated with a specific set of circulating non-HLA antibodies that can be detected, quantified, and used to follow chronic graft injury.
We undertook a carefully designed study of highly selected patients with established histologic CAI, with available serial sera and matched protocol biopsies, and with no confounding influences of delayed graft function, acute rejection, or infection on the evolution of chronic injury. Unbiased discovery of a panel of correlative non-HLA antibodies with CAI was evaluated from pretransplant and post-transplant sera in these patients. Selection of antibody targets was biased for kidney expressed antigens, and customized reverse ELISAs were generated to validate the findings in independent sera samples from an independent group of patients with CAI. These results demonstrated, verified, and validated a small panel of newly identified non-HLA antibodies that correlate not only with histologic CAI in the matched sera sample, but that also have correlative levels post-transplantation with progressive CAI and, most importantly, can predict the future development of CAI by pretransplant sampling for the same antibody panel.
Irrespective of the initial trigger, it is believed that the pathophysiology of CAI involves endothelial injury leading to an increased expression of cytokines and several other immunerelated genes, resulting in proliferative processes, remodeling, and scarring of the graft. The increased IgG antibody level of cytokines IFNG, MIG, and ITAC strengthens the belief that the 34 In this context, our observation of a significant increase in the antibody level against MIG and ITAC is important. Both MIG and ITAC are chemokine proteins that also serve as chemoattractants for leukocytes, monocytes, neutrophils, and other mononuclear cells to the site of tissue damage. 35 Upregulation of these chemokine proteins has been demonstrated to be correlated with T lymphocyte recruitment during acute and chronic rejection events. In addition, pretransplant serum levels of MIG and CXCL10 have been reported to be associated with graft failure, 36, 37 and recently our group has reported that there are high levels of circulating MIG protein in the serum of kidney and heart transplant patients at the time of acute rejection. 38 We also observed an increase in the IgG antibodies of a number of novel antigens that have not been previously reported to be relevant in organ transplantation. Some of these continue to support the activation of the immune axis as a critical trigger for CAI, such as antibodies to the Jo-1 antigen, also known as histidyl-tRNA synthetase, and are responsible for the synthesis of histidyl-transfer RNA and the migration of activated monocytes, immature dendritic cells, and activated lymphocytes. 39 An interesting antibody in CAI is the GDNF, which is involved in kidney development. Signaling by the secreted protein GDNF through the RET receptor tyrosine kinase and the GDNF family receptor a1, a GDNF co-receptor, are involved in kidney development, 40 specifically in metanephros 41 and ureteric bud development. 42 GDNF antibodies are increased in CAI and correlate with histologic CAI (Figure 3) , and baseline/pretransplant antibody levels are associated with a greater risk of CAI post-transplantation ( Figure 4 ).
In conclusion, we identified and validated a panel of circulating non-HLA antibodies in renal transplant patients that correlate with established CAI, can be serially measured posttransplant to identify which patients will develop accelerated CAI over time, and, most importantly, to stratify risk for development of CAI by measuring this antibody panel even before organ engraftment. The repertoire of the panel suggests immunologic "preconditioning" of the recipient as an important risk factor for CAI progression after engraftment because this panel of antibodies is enriched against cell-to-cell signaling and interaction as well as cell-mediated immune response, antigen presentation, and cell death (P,0.02). The altered expression of these factors may predispose the recipient to continued alloimmune injury, which then drives the turnover of chronic interstitial injury, fibrosis, and TA, with loss of graft function over time. Importantly, very similar results are noted by microarray profiling of the very same biopsy samples, from the same patient cohort, in which very coordinated expression of immune-specific genes in the allograft in the early protocol biopsy can predict the progression of CAI in the later protocol biopsy sample. 24 It is intriguing that the reactive cytokines such as MIG, ITAC, and IFNG observed in this study are also associated with AR in our previous reports. 38, 43 This observation suggests a common activation of cytokines not only as immediate trigger of inflammation and injury in AR but also as activated cytokines, in the case of CAI ( Figure 6 ). The future direction of this work requires a large-scale validation of these data in a prospective trial to assess the specificity and sensitivity of this antibody panel before transplant to assess the risk of CAI, and perhaps to subsequently titrate the immunosuppression induction and maintenance strategy for each transplant patient on the basis of the risk of post-transplant CAI.
CONCISE METHODS
Patients and Samples
We analyzed serological response on serum samples that were collected from renal transplant patients from Lucile Packard Children's Hospital, Stanford University, Stanford, California. After exclusion of patients with incidences of acute rejection (antibody mediated or cellular), infection, delayed graft function, donor pathology, and C4d-positive peritubular capillary staining on biopsies, 172 sera samples from 98 patients were selected and split into training and verification groups with a one-third (n=60 sera samples for discovery) to two-thirds split (n=112 sera samples for validation). The transplant patients included in the study were unsensitized patients, with a peak plasma renin activity ,20% and mean recipient and donor HLA match of 3.561.29. The demographic information of the transplant patients in the learning and the verification groups is summarized in Table 5 . For the discovery group, a total of 60 sera samples were used. We selected a total of 30 sera collected at time 0, 6, and 24 months post-transplantation from 10 patients with confirmed CAI by 24 months post-transplantation. The quality of the graft at the time of transplantation was excellent in this selected group of patients, with a mean Remuzzi score of 0.560.76 at the time of transplantation and a median score of 0. In the overall group, the mean CADI score was used as a semi-quantitative measure of the chronic injury grade. 44, 45 For analytical purposes, an arbitrary cutoff CADI score ,2 was used to score nonsignificant histologic injury progression; a CADI score $5.0 was used to score significant histologic injury progression. These CAI samples were compared with 30 sera samples from 10 demographically matched transplant recipients with stable graft function, with histologically clean protocol biopsies and minimal to no injury in each of the 6-and 24-month protocol biopsies. For validation of discovered antibodies by cross-sectional analysis, we identified sera samples collected from demographically matched 31 renal transplant patients with biopsy CAI and 30 without CAI. The details are summarized in Table 6 . This study was approved by the Institutional Review Board of Stanford University and the other participating centers of the clinical trial. All 172 study biopsies were blindly analyzed by a Stanford University pathologist and were graded by the Banff classification 5,46,47 for acute rejection, and intragraft C4d stains were performed 48, 49 to assess for acute humoral rejection. 50, 51 The histologic lesions of CAI were extensively identified and a semi-quantitative score for CAI applied to each biopsy, based on standardized definitions from the Banff (2), CADI, (3), and chronic calcineurin inhibitor toxicity (19) scores. For the semi-quantitative scoring criteria, chronic lesions are preceded by "c"; interstitial fibrosis is denoted as "ci" and scored as ci0-ci3; TA is denoted as "ct" and scored as ct0-ct3 based on the area of cortical tubular atrophy; glomerulopathy is denoted as "cg: and scored as cg0-cg3 based on the extent of double contours in glomerular capillary loops; and arteriolar hyalinosis is denoted as "ah" and scored as ah0-ah3 based on the extent of PAS-positive hyalinosis. On the basis of the combination of these features, a diagnosis of CAI was graded on the basis of severity as grade I (6%-25% of cortex), grade II (26%-50% of cortex), and grade III (.50% of cortex). If the biopsy of the patient showed a CAI score ,6% at the time of serum collection, the sample was considered as stable. Samples with biopsy scores for CAI between 6% and 25% were deliberately excluded to allow for clean separation of CAI samples in this discovery process.
Serum Sample Collection and Storage
Blood samples (4.5 ml) were collected in a 5-ml cryotube and incubated at room temperature for 30 minutes until the clot was formed. The sample was then centrifuged at 20003g for 5 minutes using a swinging bucket rotor. The serum was transferred to another cryotube and was stored at 280°C until use. 
Immune Response Biomarker Profiling by Protein Microarrays
We used the ProtoArray Human Protein Microarray (v4.0 and v4.1; Invitrogen, Carlsbad, CA) for this study. The slides contained a total of approximately 8200 antigens printed on each slide. The proteins included in the arrays belong to different cellular locations with a wide variety of functions. For the detection of immune response, we used manufacturer's protocol with slight changes. Briefly, the microarray slides were blocked with 5.0 ml of blocking buffer (100 mM sodium phosphate pH 7.4, 200 mM NaCl, 0.08% Triton X-100, 25% glycerol, 20 mM reduced glutathione, 1.0 mM DTT, 1% Hammarsten-grade casein) with gentle agitation in four-well trays for 1 hour at 4°C. After the blocking step, the blocking buffer was removed by aspiration and 5.0 ml diluted serum (1:150) in PBST buffer (13 PBS, 1% Hammarstengrade casein, 0.1% Tween 20) was added onto the plate to incubate for 90 minutes with gentle agitation at 4°C. In the next step, the serum sample was removed and the plates were washed five times with 5.0 ml of fresh PBST buffer with 5-minute incubations per wash with gentle agitation. A 5.0-ml portion of secondary antibody (Alexa Fluor 647 conjugate anti-human antibody) diluted in PBST buffer was added and the plates were incubated for 90 minutes with gentle agitation at 4°C. The secondary antibody solution was removed by aspiration. The plates were then washed five times with 5.0 ml of fresh PBST buffer, with 5-minute incubations per wash with gentle agitation. At the end, the slides were dried by centrifugation and scanned using an Axon GenePix 4000B scanner (Molecular Devices, Sunnyvale, CA). The data were acquired by using GenePix Pro 6.0 microarray analysis software (Molecular Devices). The slides were scanned at 635 nm with a photomultiplier gain of 600, a laser power of 100%, and a focus point of 0 mm. The .gal files were obtained from a ProtoArray central portal on the Invitrogen website (www. invitrogen.com/ProtoArray) by submitting the barcode of each protein microarray.
Statistical Analyses
Signal intensities per spot for each individual array were obtained using GenePix Pro 6.0 software. We used Prospector Analyzer 5.2 (Invitrogen Inc) to subtract the background and to normalize and to analyze the GenePix results files for each array. We used a standard cutoff Z score of 3.0. Individual antigen reactivity was ranked based on Z score above or below the mean signal for each array. Arrays from patients of a distinct clinical phenotype were analyzed as a group. Group analyses (.5 per group as suggested by the manufacturer) were made by comparing two sets of individual antibody level for every antigen present on the array using M-statistics of the Prospector Analyzer with the robust linear normalization method. 20 Differences in significance were displayed as P values, with #0.05 considered significant. We performed two-factor ANOVA on the protein array data using the CADI score and sample time as factors. The ANOVA P values were corrected for multiple hypotheses using the BenjaminiHochberg correction. We found 72 antibodies that were significantly affected by CADI score but not by time at false discovery rate ,0.2 for CADI score, of which 53 were increased in the CAI group. Hypergeometric enrichment, univariate and multivariate analyses, and logistic regression modeling were performed using customized algorithms. Ingenuity software (version 7.5; Ingenuity Systems Inc, Redwood City, CA) was used to map target antigens to canonical pathways within the Ingenuity Knowledge Base. Tissue expression of antigens against significant antibodies correlated with CAI was examined using the human protein atlas. 52-54 Figure 5 . CAI-specific antibodies are validated with immunoassays using indirect ELISA. Levels of four of the CAI-specific antibodies are assayed in CAI sera and their increased presence in biopsy-proven CAI (n=31) is analyzed by comparing their level in renal transplant patients with biopsy-proven stable graft function (n=30). Levels of (A) CSNK2A2 (P,0.002), (B) MIG (P,0.02), (C) ITAC (P,0.014), and (D) PDGFRA (P,0.0001) are increased. The increased level of antibody level of (E) CSNK2A2 and (F) MIG, along with increased CAI, is observed from ELISA on independent samples (n=17). Increases in antibody level measured by ELISA, as well as CADI score for both the antibodies are statistically significant (P,0.05). STA, stable.
Cross-Mapping of Gene IDs of the CompartmentSpecific Gene on cDNA Microarray Platform
Cross-mapping of kidney and kidney compartment-specific genes in between cDNA microarray was performed using the data published 21, 22 and the Protein Microarray V.1 was conducted using the method published earlier by our group 18 using AILUN software (http://ailun. stanford.edu/) to re-annotate probes to the most recent NCBI Entrez gene identifiers.
Development and Optimization of ELISA Assay for Validation of CAI-Based Non-HLA Antibody
For validation purposes, we developed antibody ELISA to detect serum Ig binding to MIG (also called CXCL9), ITAC (also called CXCL11), CSNK2A2, and PDGFRA following the method published previously. 11, 15 In brief, purified proteins, CSNK2A2 (cat# PV3624), PDGFRA (cat# PV3811), ITAC (cat# PHC1694), and MIG (cat# OHC1604) were acquired from Invitrogen (Carlsbad, CA). A titration with various coated amounts starting at 30.00, 15.00, 7.5, 3.75, 1.87, 0.94, 0.47, and 0 ng, respectively, was performed to determine the optimal amount to be coated onto the immunosorbent 96-well plate. The 96-well microwell ELISA plates were coated with corresponding protein in 50 ml of coating buffer (15 mM Na 2 CO 3 , 30 mM NaHCO 3 , 0.02% NaN 3 , pH 9.6). The subsequent washing and antibody incubation followed the method previously published. 11, 15 The color was developed by using AP-pNPP Liquid Substrate System for ELISA (Sigma-Aldrich, St. Louis, MO). Absorption was measured at 405 nm with a SpectraMax 190 microplate reader (Molecular Devices). To control for nonspecific binding, wells with no proteins coated were served as negative controls.
Validation of CAI-Specific Antibody by ELISA
After the optimization step, we validated the discovery made by the protein arrays on 112 sera collected from 78 renal transplant patients. There were 61 cross-sectional sera samples collected at 1 year posttransplantation from 31 unique patients with biopsy-confirmed CAI and 30 unique patients with stable biopsies (non-CAI). In addition, there were 51 serial (longitudinal) samples from 17 patients with CAI confirmed on their 6-month and 24-month biopsies, with sera samples at 0, 6, and 24 months post-transplantation. We coated 15.6 ng of the purified proteins (MIG, ITAC, CSNK2A2, and PDGFRA) onto an immunosorbent 96-well plate (NUNC brand cat# 446612). We followed a previously published protocol developed by our laboratory. 11, 15 Briefly, the 96-well microwell ELISA plates were coated with corresponding protein in 50 ml of coating buffer (15 mM Na 2 CO 3 , 30 mM NaHCO 3 , 0.02% NaN 3 , pH 9.6) and incubated overnight at 4°C. Standard curves were generated using anti-GST tag (mouse monoclonal IgG) (Millipore, Temecula, CA) and AP-conjugated AffiniPure goat antimouse IgG (Jackson ImmunoResearch, West Grove, PA). After washing the plates with TBST buffer five times, the nonspecific protein binding was blocked by 100 ml of 5% dry milk in TBST buffer for 1 hour at room temperature. After the blocking step, 50-ml serum samples (40-fold diluted with 2% milk in TBST buffer) were incubated in the wells for 1 hour at room temperature. The plates were washed five times with TBST buffer and incubated in 50 ml of AP-conjugated AffiniPure mouse antihuman IgG (Jackson ImmunoResearch). The color was developed by using AP-pNPP Liquid Substrate System for ELISA (Sigma-Aldrich). Absorption was measured at 405 nm with a SpectraMax 190 microplate reader (Molecular Devices). Statistical calculation (t test and Spearman correlation) was performed using GraphPad Prism software. P,0.05 was considered significant.
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